Kerala SK-7 lottery draw announced in Thiruvananthapuram. First prize is Rs 1 crore. Check official results released by ...

Major surgery within 4 weeks prior to first dose of RP-6306. - Uncontrolled, symptomatic brain metastases. - Uncontrolled hypertension. - Psychological, familial, sociological, or geographical ...

The company’s pipeline products include RP-3500 to treat genetically defined cancers, PKMYT1 Inhibitor RP-6306 and DNA Polymerase ? for repairing DNA breaks in homologous recombination deficient (HRD) ...

Repare Therapeutics Inc (NASDAQ: RPTX) reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) in molecularly selected advanced solid tumors.

Repare to host a virtual webcast event to discuss initial results from MYTHIC study and provide updates on the lunresertib program including early combination trial insights today at 4:30 p.m. ET ...

The Company’s pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently ...